Business
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
SOUTH SAN FRANCISCO, Calif., May 04, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Brian Walls as Vice President, Market Access and Darren M. Johnson as Vice President, Commercial Operations.
About this update from Biogen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1175,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/49eba6af2c04d5eadf9a3f42fe7af3f4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vaX0N_i.3IAHTHD.9FIXRw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMA--/https://media.zenfs.com/en/business-wire.com/49eba6af2c04d5eadf9a3f42fe7af3f4","width":960,"height":310},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Lt6K94mOpaYrXaJDse65Iw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNTA7aD03NjA-/https://media.zenfs.com/en/business-wire.com/49eba6af2c04d5eadf9a3f42fe7af3f4","width":1175,"height":380}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 04, 2026--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Brian Walls as Vice President, Market Access and Darren M. Johnson as Vice President, Commercial Operations.","length":406,"tagName":"p"},{"type":"text","content":"Mr. Walls brings more than 20 years of biopharmaceutical commercial leadership experience and has contributed to more than 18 product launches across rare, ultra-rare, oncology, neurology, and metabolic disorders. Most recently, he served as Vice President, Market Access at Applied Therapeutics, Inc. (acquired by Cycle Pharmaceuticals), where he architected the U.S. commercialization access platform for ultra-rare neurology assets. Prior to Applied Therapeutics, he served as Vice President, Market Access at Reata Pharmaceuticals (acquired by Biogen), leading enterprise access strategy for the launch of SKYCLARYS. Earlier, Mr. Walls served as Executive Director, Market Access at Progenics Pharmaceuticals (acquired by Lantheus), where he secured New Technology Add-on Payment (NTAP) approval for AZEDRA, and as Head of Value & Access at Alexion Pharmaceuticals (acquired by AstraZeneca), where he led U.S. access strategy for the dual ultra-rare launches of Strensiq and Kanuma and the registration launch of Soliris in nephrology. He has also held senior commercial roles at Amgen Incorporated and GlaxoSmithKline. Mr. Walls earned his MBA from the University of Indianap...